Pfizer Inc. (PFE)
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer beats Q4 profit estimates despite COVID-19 sales decline
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, exceeding analyst expectations on adjusted earnings even as sales of its COVID-19 products fell. The pharmaceutical company's beat on profit wasn't enough to offset concerns about declining COVID-19 revenue and future growth uncertainties, with shares dropping 4.3% on Tuesday morning in New York.
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago.
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.
Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand
Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Passive Income Investors Will Love These Cheap Dividend Stocks
Passive income can help secure your retirement, but building a dependable income is not easy.
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.
